Autologous Peripheral Blood Stem Cell Transplantation

PROCEDURE6 trials

Conditions

Anemia, Hemolytic, AutoimmuneAutoimmune Thrombocytopenic PurpuraChurg-Strauss SyndromeGiant Cell ArteritisGraft Versus Host DiseaseHodgkin LymphomaHypersensitivity VasculitisJuvenile Rheumatoid Arthritis

Phase 1

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

CompletedNCT00482846

Barbara Ann Karmanos Cancer InstituteMucositis, Multiple Myeloma

Start: 2007-06-30End: 2012-09-30Updated: 2014-04-15

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

NCT02280993

Marjolein SpieringHodgkin Lymphoma, Refractory, Relapse

Start: 2014-05-31End: 2020-05-31Target: 72Updated: 2018-03-13

Phase 2

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

CompletedNCT00075621

Boston Medical CenterMultiple Myeloma

Start: 2000-08-31End: 2020-09-04Updated: 2020-09-17

Phase 3

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

CompletedNCT02288741

WiSP Wissenschaftlicher Service Pharma GmbHMultiple Myeloma

Start: 2001-08-31End: 2012-09-30Updated: 2014-11-11

Unknown Phase

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055

Fairview University Medical CenterAnemia, Hemolytic, Autoimmune, Autoimmune Thrombocytopenic Purpura, Churg-Strauss Syndrome +11

Start: 2000-03-31Target: 10Updated: 2005-06-24

Effects of Exercise in Combination With Epoetin Alfa

CompletedNCT00577096

University of ArkansasMultiple Myeloma

Start: 2001-10-31End: 2004-06-30Updated: 2015-04-06

Blood Advances2023-09-1816 citations

Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Blood2022-11-151 citations

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.

2022-10-1415 citations

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Haematologica2020-04-0992 citations